Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SCTB41 plus trifluridine/tipiracil in advanced gastrointestinal tumors after failure of standard therapy
CTR20261346Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- May 2026
- Modality
- Small Molecules, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB41, trifluridine + tipiracil in gastrointestinal cancer, sponsored by Sinocelltech Group Limited. Started May 2026; status: active.
02
Drugs
SCTB41trifluridine + tipiracil
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on CTR20261346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261346.